Literature DB >> 17907035

IO versus IV access while wearing personal protective equipment in a HazMat scenario.

Joe Suyama1, Christian C Knutsen, William E Northington, Michael Hahn, David Hostler.   

Abstract

OBJECTIVE: Determine the time difference obtaining intraosseous (IO) versus intravenous (IV) access while wearing personal protective equipment (PPE) in simulated HazMat scenarios.
METHODS: Twenty-two EMT-P providers established anterior tibial IO access using the EZ-IO system and routine antecubital IV access in three mannequin and PPE HazMat scenarios: 1) provider and mannequin not in PPE, 2) only provider in Level C PPE, and 3) provider and mannequin both wearing Level C PPE. Primary outcome measures were the average time in seconds for skin access, vascular access, and fluid infusion with each method in these configurations.
RESULTS: For the provider and mannequin not in PPE condition, needle to skin time favored the IV (6.2 vs. 9.3 seconds; p < 0.001). whereas vascular access time (12.8 vs. 36.3 seconds; p < 0.001) and fluid infusion time (26.2 vs. 36.5 seconds; p = 0.02) favored the IO approach. For the provider in PPE and mannequin not in PPE condition, needle to skin times were similar for IO and IV (10.4 vs. 12.7 seconds; p = 0.591), whereas vascular access time (14.0 vs. 46.0 seconds; p < 0.001) and fluid infusion time (28.3 vs. 45.7 seconds; p < 0.001) both favored the IO approach. With the provider and mannequin in PPE, needle to skin time (12.7 vs. 24.9 seconds; p < 0.001), vascular access time (16.9 vs. 62.7 seconds; p < 0.001), and fluid infusion time (29.5 vs. 66.1 seconds; p < 0.001) all favored the IO approach. Fluid infusion times for the provider not in and in PPE (26.2 vs. 28.3 seconds; p < 0.05) with the mannequin not in PPE revealed no significant time burden associated with using the EZ-IO device with the provider in PPE.
CONCLUSIONS: Overall, the EZ-IO system under HazMat conditions provides vascular access and fluid more quickly than standard intravenous access. When providers and mannequins were both in PPE, the time differential between IO and IV access was the greatest, favoring the IO approach. Donning PPE did not hinder the providers' use of the EZ-IO device and may be useful for obtaining vascular access when wearing PPE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17907035     DOI: 10.1080/10903120701536982

Source DB:  PubMed          Journal:  Prehosp Emerg Care        ISSN: 1090-3127            Impact factor:   3.077


  5 in total

Review 1.  Clinical update on COVID-19 for the emergency clinician: Cardiac arrest in the out-of-hospital and in-hospital settings.

Authors:  William J Brady; Summer Chavez; Michael Gottlieb; Stephen Y Liang; Brandon Carius; Alex Koyfman; Brit Long
Journal:  Am J Emerg Med       Date:  2022-04-27       Impact factor: 4.093

2.  Out-of-hospital cardiac arrest treated by emergency medical service teams during COVID-19 pandemic: A retrospective cohort study.

Authors:  Magdalena J Borkowska; Jacek Smereka; Kamil Safiejko; Klaudiusz Nadolny; Maciej Maslanka; Krzysztof J Filipiak; Milosz J Jaguszewski; Lukasz Szarpak
Journal:  Cardiol J       Date:  2020-11-03       Impact factor: 2.737

3.  Comparison of four different intraosseous access devices during simulated pediatric resuscitation. A randomized crossover manikin trial.

Authors:  Karol Bielski; Lukasz Szarpak; Jacek Smereka; Jerzy R Ladny; Steve Leung; Kurt Ruetzler
Journal:  Eur J Pediatr       Date:  2017-05-12       Impact factor: 3.183

4.  Which intravascular access should we use in patients with suspected/confirmed COVID-19?

Authors:  Jacek Smereka; Lukasz Szarpak; Krzysztof J Filipiak; Milosz Jaguszewski; Jerzy R Ladny
Journal:  Resuscitation       Date:  2020-04-15       Impact factor: 5.262

5.  A Randomized Cadaver Study Comparing First-Attempt Success Between Tibial and Humeral Intraosseous Insertions Using NIO Device by Paramedics: A Preliminary Investigation.

Authors:  Lukasz Szarpak; Zenon Truszewski; Jacek Smereka; Paweł Krajewski; Marcin Fudalej; Piotr Adamczyk; Lukasz Czyzewski
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.